Cargando…

New Antivirals and Immune Therapies for COVID-19 Infection

Detalles Bibliográficos
Autores principales:	Miro, Jose M., Torres, Antoni, Paredes, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SEPAR. Published by Elsevier España, S.L.U. 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012508/ https://www.ncbi.nlm.nih.gov/pubmed/35501220 http://dx.doi.org/10.1016/j.arbres.2022.03.008

Ejemplares similares

Antivirals in the time of COVID-19 – not as easy as it looks!
por: Trémolières, F.
Publicado: (2021)

Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared
por: Parums, Dinah V.
Publicado: (2023)

Combining immunomodulators and antivirals for COVID-19 – Authors' reply
por: Almansa, Raquel, et al.
Publicado: (2021)

Covid-19 challenges to immune investigations and therapies
por: Talmadge, James E., et al.
Publicado: (2021)

A New Look at the LDRT treatment for COVID-19 Associated Pneumonia: The Issues of Antiviral Resistance and Virus Spread-Ability
por: J. J., Bevelacqua, et al.
Publicado: (2020)

COVID-19 infection: the perspectives on immune responses
por: Shi, Yufang, et al.
Publicado: (2020)

Hepatitis C virus infection in patients with hemophilia in Korea: Is antiviral therapy effective and safe?
por: Rou, Woo Sun, et al.
Publicado: (2015)

Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review
por: Cantini, Fabrizio, et al.
Publicado: (2020)

Antiviral Therapy of COVID-19
por: Gudima, Georgii, et al.
Publicado: (2023)

The Role of Oral Antivirals for COVID-19 Treatment in Shaping the Pandemic Landscape
por: Anastassopoulou, Cleo, et al.
Publicado: (2022)

Respiratory infections
por: Niederman, Michael S., et al.
Publicado: (2022)

Computational drug repurposing in the age of COVID-19: mixing antiviral cocktails in silico
por: Diao, James A., et al.
Publicado: (2022)

Special Issue “Efficacy and Safety of Antiviral Therapy”
por: Colpani, Agnese, et al.
Publicado: (2023)

PCR detection and new therapies for COVID-19
por: Iwata, Takanori
Publicado: (2020)

Autoantibodies in COVID‐19 correlate with antiviral humoral responses and distinct immune signatures
por: Taeschler, Patrick, et al.
Publicado: (2022)

Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential
por: Rivera-Torres, José, et al.
Publicado: (2019)

Virus-, host-, immune-based targets for COVID-19 therapy
por: Liu, Wei, et al.
Publicado: (2020)

Home Nitric Oxide Therapy for COVID-19
por: Alvarez, Roger A., et al.
Publicado: (2020)

The Complex Interplay Relationship between HCV Infection, Direct-Acting Antiviral Therapy, and Hepatocellular Carcinoma Occurrence
por: Cavalletto, Luisa, et al.
Publicado: (2023)

Are Viral Vectors Any Good for RNAi Antiviral Therapy? †
por: Lundstrom, Kenneth
Publicado: (2020)

Frontiers in antiviral therapy and immunotherapy
por: Heaton, Steven M
Publicado: (2020)

Immune Responses and Breakthrough Infections After COVID-19 Vaccination
por: Kwon, Ki Tae
Publicado: (2023)

Steroid therapy and antiviral treatment in SARSCoV-2 pneumonia: clinical contexts and indications
por: Torres, Antoni, et al.
Publicado: (2022)

Antiviral therapy and immunotherapy of COVID-19
por: Crespillo, Clara, et al.
Publicado: (2021)

Can Allergen Immunotherapy Improve Antiviral Immunity in Patients with Allergic Asthma?
por: Upham, John W.
Publicado: (2023)

COVID-19 and Dentistry: Enhancing Knowledge and Attitudes towards Infections, Immunity, and Vaccination
por: Pawar, Ajinkya M, et al.
Publicado: (2023)

Further standardization and safety issues for antiviral therapy during pregnancy
por: Zhaori, Getu
Publicado: (2020)

Broad-Spectrum Antivirals and Antiviral Drug Combinations
por: Oksenych, Valentyn, et al.
Publicado: (2022)

Are previous viral infections important for the COVID-19 outcomes?
por: Torres-Flores, Jesus, et al.
Publicado: (2021)

Oral antivirals for mild–moderate COVID-19: a panacea or a logistical and clinical conundrum?
por: Coombes, Ian D, et al.
Publicado: (2022)

Appropriate use of antimicrobial therapy for COVID-19 co-infection
por: Lai, Chih-Cheng, et al.
Publicado: (2021)

Broad-Spectrum Antivirals and Antiviral Combinations: An Editorial Update
por: Kainov, Denis, et al.
Publicado: (2022)

A new year and new infection prevention and control opportunities from the COVID-19 legacy
por: Winzor, G., et al.
Publicado: (2023)

Does herbal therapy for COVID-19 have implications for forensic practice?
por: Byard, Roger W., et al.
Publicado: (2021)

New emerging SARS-CoV-2 variants and antiviral agents
por: Vitiello, A., et al.
Publicado: (2023)

Antivirals and Vaccines
por: Taveira, Nuno
Publicado: (2023)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

New Insights for Immune-Based Diagnosis and Therapy for Infectious Diseases
por: Sautto, Giuseppe A., et al.
Publicado: (2017)

Interim Guidelines on Antiviral Therapy for COVID-19
por: Kim, Sun Bean, et al.
Publicado: (2020)

Early triple antiviral therapy for COVID-19
por: Lee, Nelson, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_21jfrf5o2k2ea8s5e0oao8k15l